Kawashima H, Nishimata S, Ishii C, Yamanaka G, Kashiwagi Y, Takekuma K, Hoshika A, Watanabe Y. New treatment of free-radical scavenger in adrenoleukodystrophy.
J Clin Pharm Ther 2011;
36:412-5. [PMID:
21463348 DOI:
10.1111/j.1365-2710.2011.01267.x]
[Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE
Adrenoleukodystrophy (ALD) is an X-linked disorder and characterized by the accumulation of saturated very long-chain fatty acids. Treatment is still unsatisfactory. Our objective is to report on the effect of the free-radical scavenger, edaravone, in a patient with ALD.
CASE SUMMARY
The patient was given edaravone intravenously twice. D-ROM in cerebral spinal fluid decreased dramatically, and a shortening of neuronal transmission time as estimated on somatosensory evoked potential was observed. After terminating the treatment, his symptoms progressively reappeared.
WHAT IS NEW AND CONCLUSION
This is the first report of the use of edaravone in ALD. The drug is apparently effective in improving symptoms of ALD and should be evaluated more formally.
Collapse